

12th November, 2021

To
Department of Corporate Services
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001
Scrip Code: **BSE - 524500**

To
Corporate Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1, G Block,
BKC, Bandra (E), Mumbai 400 051
Scrip Code: **NSE - KILITCH**

Sub: **Outcome of Board Meeting held on 12th November, 2021**

Dear Sir/Madam,

In continuation to our letter dated 2nd November 2021, we wish to inform you that pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the company, at its meeting held today i.e. 12th November, 2021, have considered and approved the following-

1. The Un-audited financial results of the company for the quarter and half year ended 30th September 2021;

In this connection please find enclosed the copy of Un-audited Standalone & Consolidated financial Results of the Company for the quarter and half year ended 30th September 2021 along with Limited Review Report by the Statutory Auditors of the Company as "Annexure-I".

The meeting commenced at 03: 00 P.M. and concluded at 07: 15 P.M.

The above is for information and dissemination to the public at large.

Thanking You,

Yours Faithfully,
For Kilitch Drugs (India) Limited




Mukund Mehta
(Managing Director)
DIN:00147876
Encl: as above





Limited Review Report on Unaudited Quarterly and year to date Financial Results of Kilitch Drugs (India) Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

The Board of Directors of

Kilitch Drugs (India) Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Kilitch Drugs (India) Limited** (the 'Company') for the quarter ended 30th September, 2021 and year to date from April 1, 2021 to September 30, 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").

2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition & measurement principles laid down in the Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules thereafter and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We draw attention to Note 4 of the Statement, which describes the company's management evaluation of impact of Covid 19 pandemic on the its business, logistics etc. The Management has made reasonable judgements and estimates from internal and external sources of information including economic forecasts, inter alia, in determining carrying amounts of trade receivables, property, plant & equipment, inventories and other financial assets while preparing the financial results as of and for the quarter and half year ended 30th September, 2021.

Our conclusion on the Statement is not modified in respect of these matters.



5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **SURYAPRAKASH MURYA & Co.**

Chartered Accountants

Firm Registration No. 147410W



(Suryaprakash Maurya)



Proprietor

Membership No. 178258

Place : Mumbai

UDIN : 21178258AAAAFM7043

Dated: November 12, 2021


KILITCH DRUGS (INDIA) LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2021

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701
Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

(Rs. in Lakhs)

Sr. No.	Particulars	STANDALONE					
		Three Months Ended			Six Months Ended		Year Ended
		30/09/2021	30/06/2021	30/09/2020	30/09/2021	30/09/2020	31/03/2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	Net Sales/ Income from operations	2,305.40	1,951.15	1,818.67	4,256.55	2,855.45	7,001.68
	Other Income	58.65	148.41	98.25	207.06	186.69	419.43
	Total Income	2,364.05	2,099.56	1,916.92	4,463.61	3,042.14	7,421.11
2	Expenses						
	(a) Cost of Materials Consumed	1,294.87	1,079.08	820.01	2,373.95	1,507.52	3,797.46
	(b) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(30.02)	13.75	81.53	(16.27)	132.73	108.81
	(c) Employee Benefit Expenses	156.45	140.10	131.66	296.55	246.55	521.74
	(d) Finance Cost	12.31	12.75	17.84	25.06	47.16	75.44
	(e) Depreciation and Amortisation Expenses	23.41	23.30	28.45	46.71	55.87	114.10
	(f) Export Product Registration/Commission	151.99	147.55	76.58	299.54	126.78	448.30
	(g) Other Expenses	527.79	327.71	440.02	855.50	677.84	1,604.43
	Total Expenses	2,136.80	1,744.24	1,596.09	3,881.04	2,794.46	6,670.28
3	Profit / (Loss) before Exceptional items (1-2)	227.25	355.32	320.83	582.57	247.68	750.83
4	Exceptional Items	-	-	-	-	-	-
5	Profit / (Loss) from ordinary activities before tax (3+4)	227.25	355.32	320.83	582.57	247.68	750.83
6	Less: Tax Expenses:-						
	Current Tax	53.94	61.45	67.50	115.39	67.50	166.55
	Deferred Tax	(11.67)	5.18	(17.80)	(6.49)	(36.53)	(31.26)
7	Net Profit / (Loss) after Tax for the period from Continuing Operations (5-6)	184.98	288.69	271.13	473.67	216.71	615.54
8	Other Comprehensive Income (after tax)	134.61	149.11	96.59	283.72	281.02	522.87
9	Total Comprehensive Income (after taxes) (7+8)	319.59	437.80	367.72	757.39	497.73	1,138.41





10	Paid-Up equity share capital (Face Value Rs 10 per share)	1,556.20	1,556.20	1,547.91	1,556.20	1,547.91	1,549.45
11	Other Equity						14,743.96
12	Earnings per share						
	(a) Basic (not annualised)	1.19	1.86	1.75	3.05	1.40	3.98
	(b) Diluted (not annualised)	1.19	1.86	1.75	3.05	1.40	3.98

Notes:

- The above Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 12th November, 2021.
 - The Statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
 - The Company is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
 - The Company continues to monitor the impact of Covid-19 on its business, including its impact on customers, supply-chain, employees and logistics. The Management has exercised due care and made reasonable judgements and estimates from internal and external sources of information including economic forecasts, inter alia, in determining carrying amounts of trade receivables, property, plant & equipment, inventories and other financial assets while preparing the financial results as of and for the quarter/half year ended 30th September, 2021. The Company based on current estimates expects to recover the carrying amount of the above assets, net of provisions established.
- In view of the uncertainties regarding the nature and duration of the ongoing COVID-19 Pandemic, we are unable to predict the future impact on our business operations. However, the Company will continue to closely monitor the situation and take appropriate measures in an attempt to mitigate any adverse impact on its future economic conditions.
- The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods.

Place : Mumbai
Dated: 12th November 2021




For and on behalf of the Board of Directors

Mukund P. Mehta
Mukund P. Mehta
Managing Director


KILITCH DRUGS (INDIA) LIMITED

Balance Sheet
As at 30th September, 2021

(Rs. in Lakhs)		
Particulars	As at 30th September, 2021	As at 31st March, 2021
	UNAUDITED	AUDITED
ASSETS		
Non-current assets		
- Property, Plant and Equipment	638.69	679.07
- Capital work-in-progress	-	-
- Other Intangible Assets	15.98	15.40
Financial assets		
- Investments	7,026.62	7,010.04
- Loans/Advances	4,576.45	4,400.31
- Other Financial Assets	179.01	176.34
Deferred tax assets (Net)	133.93	127.44
(A)	12,570.68	12,408.60
Current Assets		
- Inventories	433.16	358.61
Financial assets-		
- Investments	4,258.89	3,640.05
- Trade Receivables	2,199.40	2,291.84
- Cash & Cash Equivalents	128.73	577.39
- Other Financial Assets	-	1.97
Other Current Assets	707.00	306.30
(B)	7,727.18	7,176.16
TOTAL ASSETS (A + B)	20,297.86	19,584.76
EQUITY AND LIABILITIES		
Equity		
- Equity Share Capital	1,556.20	1,549.45
- Other Equity	15,501.34	14,743.96
Equity attributable to Owner	17,057.54	16,293.41
(A)	17,057.54	16,293.41
Non-Current liabilities		
- Provisions	37.75	38.06
Current liabilities		
Financial Liabilities		
- Borrowings	1,747.25	1,470.68
- Trade Payables	-	-
Micro and Small Enterprises	-	-
Others	909.29	1,355.74
- Other Financial Liabilities	3.88	3.88
Provisions	96.76	80.60
Current Tax Liabilities (Net)	400.97	262.30
Other Current Liabilities	44.42	80.09
(B)	3,240.32	3,291.35
TOTAL LIABILITIES (A + B)	20,297.86	19,584.76



Place : Mumbai
Dated: 12th November 2021








For and on behalf of the Board of Directors
Mukund P. Mehta
Managing Director

KILITCH DRUGS (INDIA) LIMITED

Cash Flow Statement for half year ended 30th September, 2021

Particulars	(Rs. in Lakhs)			
	half year ended 30th September, 2021		Year Ended 31st March 2021	
	[Rs.]	[Rs.]	[Rs.]	[Rs.]
	UNAUDITED		AUDITED	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Net Profit / (Loss) before extraordinary items and tax		582.57		750.83
<u>Adjustments for:</u>				
Depreciation and amortisation	46.71		114.10	
Interest income	(97.30)		(177.34)	
Dividend income	(0.29)		(5.55)	
(Profit)/Loss on sale of Investments	(40.39)		(120.31)	
Sundry Balances written back	-		(1.03)	
Provision for Gratuity & Leave Encashment	2.25		4.83	
Employee Stocks Option Cost	-		(15.74)	
Interest Expenses	25.06		75.44	
Bad Debts / Provision for Doubtful Debts	42.24		153.44	
(Profit) / Loss from Investment in Partnership Firm	-		0.20	
Net unrealised exchange (gain) / loss	76.16	54.44	1.25	
Operating profit / (loss) before working capital changes		637.01		780.11
<u>Changes in working capital:</u>				
<u>Operating Assets:</u>				
Inventories	(74.55)		197.06	
Trade receivables	(25.99)		(745.97)	
Other current assets	(400.71)		(16.61)	
Deposits & advances	(3.44)		(8.03)	
Other financial assets	1.97		0.57	
<u>Operating Liabilities:</u>				
Trade payables	(446.46)		566.16	
Other current liabilities	(35.66)		19.91	
Provisions	13.61	(971.23)	(3.97)	9.12
Gross cash flow from / (used in) operating activities		(334.22)		789.23
Direct Taxes (Paid) / refunded		(76.40)		(101.25)
Net cash flow from / (used in) operating activities (A)		(410.62)		687.98
B. CASH FLOW FROM INVESTING ACTIVITIES				
Fixed assets purchased	(6.91)		(41.93)	
Loans/Advances to related Parties	(172.69)		(525.98)	
Proceeds/(Purchases) (Net) of Current Investments	(195.04)		(43.47)	
Proceeds/(Purchases) (Net) of Non-Current Investments	(16.58)		16.27	
Movement in other Bank balance	(2.67)		(122.51)	
Interest received	97.30		177.34	
Dividend received	0.29		5.55	
		(296.30)		(534.73)
		(296.30)		(534.73)
Net cash flow from / (used in) investing activities (B)		(296.30)		(534.73)



C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from Shares issued [incl. ESOPs]	6.75		6.04	
Proceeds from Borrowings (Net of Repayments)	276.57		219.46	
Interest paid	(25.06)		(75.44)	
Dividends paid (Inclusive of tax on Dividend) re-credited	(0.00)		1.81	
Net cash flow from / (used in) financing activities (C)		258.26		151.87
Net increase / (decrease) in Cash and cash equivalents (A+B+C)		(448.66)		305.12
Cash and cash equivalents at the beginning of the year		577.39		272.27
Cash and cash equivalents at the end of the year		128.73		577.39
Cash and cash equivalents at the end of the year *				
* Comprises:				
(a) Cash on hand		1.13		0.71
(b) Balances with banks				
(i) In current accounts		123.72		572.80
(ii) In earmarked accounts		3.88		3.88
		128.73		577.39
<div style="display: flex; justify-content: space-between; align-items: flex-start;"> <div style="text-align: center;">  <p>Place : Mumbai Dated: 12th November 2021</p> </div> <div style="text-align: center;"> <p>For and on behalf of the Board of Directors</p>  <p>Mukund P. Mehta Managing Director</p>  </div> </div>				



Limited Review Report on Unaudited Quarterly and year to date Consolidated Financial Results of Kilitch Drugs (India) Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

**The Board of Directors of
Kilitch Drugs (India) Limited**

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **Kilitch Drugs (India) Limited** ("the Parent"), and its' subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30th September, 2021 and year to date from April 1, 2021 to September 30, 2021 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This statement which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether Statement is free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, to the extent applicable.

4. The Statement includes the results of entities as given below:

List of Subsidiaries:

1. Monarchy Healthserve Private Limited
2. Kilitch Estro Biotech PLC – Foreign Subsidiary




5. (a) We did not review the interim financial results and other financial information in respect of one subsidiary whose interim financial results/information reflects, total assets of Rs. 2,202.91 Lakhs, total revenues of Rs. Nil and Rs. 22.41 Lakhs, total net profit/(loss) after tax of Rs. (11.76) Lakhs and Rs. (43.63) Lakhs and total comprehensive income/(loss) of Rs. (11.76) Lakhs and Rs. (43.63) Lakhs for the quarter ended 30th September, 2021 and for the period from 1st April, 2021 to 30th September, 2021, respectively and net cash outflow of Rs. 0.63 Lakhs for the period from 1st April, 2021 to 30th September, 2021. These interim financial results and other financial information have been reviewed by other auditors, whose reports have been furnished to us by the management of the Company and our conclusion in so far as it relates to the affairs of such subsidiary is based solely on the report of other auditors.
6. (b) The Statement includes interim financial results and other financial information in respect of one foreign subsidiary which reflects, total assets of Rs. 9,039.46 Lakhs, total revenues of Rs. 32.39 Lakhs and Rs. 77.59 Lakhs, total net profit/(loss) after tax of Rs. 128.75 Lakhs and Rs. (13.09) Lakhs and total comprehensive income/(loss) of Rs. 128.75 Lakhs and Rs. (13.09) Lakhs for the quarter ended 30th September, 2021 and for the period from 1st April, 2021 to 30th September, 2021, respectively and net cash outflow of Rs. 184.82 Lakhs for the period from 1st April, 2021 to 30th September, 2021 as considered in the consolidated financial results. These financial statements have been furnished to us by the management and our opinion on the statement, in so far as it relates to the amounts included in respect of this subsidiary is solely based on such unaudited financial statements as certified by the management. Our conclusion on the Statement is not modified in respect of the above matter.
7. We draw attention to Note 5 of the Statement, which describes the Group's management evaluation of impact of Covid 19 pandemic on its business, logistics etc. The Management has made reasonable judgements and estimates from internal and external sources of information including economic forecasts, inter alia, in determining carrying amounts of trade receivables, property, plant & equipment, inventories and other financial assets while preparing the financial results as of and for the quarter and half year ended 30th September, 2021.
Our conclusion on the Statement is not modified in respect of these matters.
8. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on management certified financial statements referred in paragraph 5 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SURYAPRAKASH MURYA & Co.

Chartered Accountants

Firm Registration No. 147410W



(Suryaprakash Maurya)

Proprietor

Membership No. 178258

Place : Mumbai

UDIN : 21178258AAAAFN9080

Dated: November 12, 2021




KILITCH DRUGS (INDIA) LIMITED

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2021

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701
Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

(Rs. In Lakhs)

Sr. No.	Particulars	CONSOLIDATED					
		Three Months Ended			Six Months Ended		Year Ended
		30/09/2021 Unaudited	30/06/2021 Unaudited	30/09/2020 Unaudited	30/09/2021 Unaudited	30/09/2020 Unaudited	31/03/2021 Audited
1	Income						
	Net Sales/Income from Operations	2,357.05	1,962.49	1,807.20	4,319.54	2,826.37	6,852.31
	Other Income	16.81	105.38	42.21	122.19	79.16	266.73
	Total Income	2,373.86	2,067.87	1,849.41	4,441.73	2,905.53	7,119.04
2	Expenses						
	Cost of Materials Consumed	790.72	1,637.94	771.22	2,428.66	1,442.32	3,621.91
	Variation in inventories of finished goods, work-in-progress and Stock-in-Trade	505.42	(538.61)	81.53	(33.19)	132.73	108.81
	Employee Benefit Expenses	157.06	140.99	132.23	298.05	247.69	523.98
	Finance Cost	12.31	12.75	17.84	25.06	47.16	75.44
	Depreciation and Amortisation Expenses	69.80	44.41	49.58	114.21	98.13	198.61
	Export Product Registration/Commission	151.99	147.55	76.58	299.54	126.78	448.30
	Other expenses	386.14	484.25	449.89	870.39	692.32	1,630.03
	Total Expenses	2,073.44	1,929.28	1,578.87	4,002.72	2,787.13	6,607.08
3	Profit/(Loss) before Exceptional items (1-2)	300.42	138.59	270.54	439.01	118.40	511.96
4	Exceptional Items	-	-	-	-	-	-
5	Profit/(Loss) from ordinary activities before tax (3+4)	300.42	138.59	270.54	439.01	118.40	511.96
6	Less : Tax Expenses						
	Current Income Tax	53.94	61.45	67.50	115.39	67.50	166.55
	Deferred Tax	(11.66)	5.18	(17.75)	(6.48)	(36.52)	(31.25)
7	Profit/(Loss) after tax for the period from continuing operations (5-6)	258.14	71.96	220.79	330.10	87.42	376.66
8	Other Comprehensive Income (after Tax)	134.60	149.12	96.59	283.72	281.02	522.87
9	Total Comprehensive Income (after tax) (7+8)	392.74	221.08	317.38	613.82	368.44	899.53




Handwritten signature

10	Net Profit / (Loss) attributable to						
	a) Owner of the Company	215.65	118.77	208.17	334.42	74.80	367.11
	b) Non Controlling interest	42.49	(46.81)	12.62	(4.32)	12.62	9.55
11	Other Comprehensive Income attributable to						
	a) Owner of the Company	134.60	149.12	96.59	283.72	281.02	522.87
	b) Non Controlling interest	-	-	-	-	-	-
12	Total Income attributable to						
	a) Owner of the Company	350.25	267.89	304.76	618.14	355.82	889.98
	b) Non Controlling interest	42.49	(46.81)	12.62	(4.32)	12.62	9.55
13	Paid-Up equity share capital (Face Value Rs. 10 per share)	1,556.20	1,556.20	1,547.91	1,556.20	1,547.91	1,549.45
14	Other Equity						11,163.42
15	Earning per share						
	(a) Basic (not annualised)	1.39	0.76	1.34	2.15	0.48	2.37
	(b) Diluted (not annualised)	1.39	0.76	1.34	2.15	0.48	2.37

Notes:

- The above unaudited Consolidated Financial Results of the Group for the quarter and half year ended 30th September, 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 12th November, 2021.
- The Statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The Group is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
- The green field project of the Group under its foreign subsidiary - Kilitch Estro Biotech PLC, at Oromia Special Zone, Ethiopia, started the commercial production of Cephalosporins Injectables w.e.f 26th July 2021. The sales/revenue from the said project, however, have not yet commenced as on 30th September, 2021 and are accordingly not reflecting in the said results.
- The Group continues to monitor the impact of Covid-19 on its business, including its impact on customers, supply-chain, employees and logistics. The Management has exercised due care and made reasonable judgements and estimates from internal and external sources of information including economic forecasts, inter alia, in determining carrying amounts of trade receivables, property, plant & equipment, inventories and other financial assets while preparing the financial results as of and for the quarter and half year ended 30th September, 2021. The Group based on current estimates expects to recover the carrying amount of the above assets, net of provisions established. In view of the uncertainties regarding the nature and duration of the ongoing COVID-19 Pandemic, we are unable to predict the future impact on our business operations. However, the Group will continue to closely monitor the situation and take appropriate measures in an attempt to mitigate any adverse impact on its future economic conditions.
- The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods.



For and on behalf of the Board of Directors
Mukund P. Mehta
Director

Place: Mumbai
Date: 12th November, 2021

KILITCH DRUGS (INDIA) LIMITED

STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2021

CIN:L24239MH1992PLC066718

(Rs. In Lacs)

Particulars	As at 30th September, 2021	As at 31st March, 2021
	UNAUDITED	AUDITED
ASSETS		
Non-current assets		
Property, plant and Equipment	724.67	790.41
Capital work-in-progress	6,507.98	6,547.98
Other Intangible assets	2,164.47	2,206.02
Financial assets		
- Investments	2,404.92	2,388.34
- Loans/Advances	47.59	44.14
- Other Financials Assets	179.01	176.34
Deferred tax assets (Net)	134.35	127.87
(A)	12,162.99	12,281.10
Current assets		
Inventories	433.16	358.61
Financial assets		
- Investments	4,258.89	3,640.05
- Trade and other receivables	2,225.55	2,291.84
- Cash and cash equivalents	615.94	1,250.05
- Other Financials Assets	-	1.97
Other current assets	1,052.18	493.93
(B)	8,585.72	8,036.45
TOTAL ASSETS (A + B)	20,748.71	20,317.55
EQUITY AND LIABILITIES		
Equity		
Equity Share capital	1,556.20	1,549.45
Other Equity	11,788.41	11,163.42
Equity attributable to the owners	13,344.61	12,712.87
Non-controlling interest	234.06	235.00
(A)	13,578.67	12,947.87
Liabilities		
Non - Current Liabilities		
Provisions	37.75	38.06
Current liabilities		
Financial liabilities		
- Borrowings	1,756.95	1,480.38
- Trade Payables		
Micro and Small Enterprises		
Others	4,825.18	5,365.46
- Other financial liabilities	3.88	3.88
Provisions	98.93	82.76
Current tax Liabilities (Net)	400.97	262.30
Other current liabilities	46.38	136.84
(B)	7,170.04	7,369.68
TOTAL EQUITY AND LIABILITIES (A + B)	20,748.71	20,317.55

For and on behalf of the Board of Directors

Mukund P. Mehta
Managing Director




Place : Mumbai
Dated : 12th November



KILITCH DRUGS (INDIA) LIMITED
CONSOLIDATED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30TH SEPTEMBER, 2021

Rs. (In Lacs)

Particulars	For the half Year ended 30th September, 2021		For the Year ended 31st March, 2021	
	UNAUDITED	AUDITED	UNAUDITED	AUDITED
	[Rs.]	[Rs.]	[Rs.]	[Rs.]
A. CASH FLOW FROM OPERATING ACTIVITIES				
Net Profit / (Loss) before extraordinary items and tax		439.01		511.96
Adjustments for:				
Depreciation and amortisation	114.21		198.61	
Interest income	(10.45)		(17.03)	
Dividend income	(0.29)		(5.55)	
(Profit)/Loss on sale of Investments	(40.39)		(120.31)	
Share of (Profit)/ Loss from Partnership Firm	-		0.20	
Sundry Balances written back	-		(1.03)	
ESOP Cost	-		(15.74)	
Provision for Gratuity & Leave Encashment	2.25		4.83	
Interest Expenses	25.06		75.44	
Bad Debts / Provision for Doubtful Debts	42.24		153.29	
Net unrealised exchange (gain) / loss	76.16		7.25	
Operating profit / (loss) before working capital changes		208.79		279.96
		647.80		791.92
Changes in working capital:				
Operating Assets:				
Inventories	(74.55)		197.06	
Trade receivables	(52.12)		(866.48)	
Other financial Assets	(400.71)		64.18	
Other current assets	(247.20)		(183.77)	
Deposits/Advances	1.97		(8.13)	
Operating Liabilities:				
Trade payables	(445.72)		4,656.09	
Other current liabilities	(12.33)		18.44	
Short-term provisions	13.61		(2.17)	
Gross cash flow from / (used in) operating activities		(1,217.05)		3,875.22
Direct Taxes (Paid) / refunded		(569.25)		4,667.14
		(76.40)		(101.25)
Net cash flow from / (used in) operating activities		(645.65)		4,565.89
B. CASH FLOW FROM INVESTING ACTIVITIES				
Capital expenditure on fixed assets, including capital advances	(43.17)		(3,629.79)	
Proceeds (Net) from the sale of Current Investments	(195.04)		(43.47)	
(Purchase)/Sale (Net) of long-term investments	(16.58)		16.27	
Movement in other Bank balance	(2.67)		(122.51)	
Interest received	10.45		17.03	
Dividend received	0.29		5.55	
		(246.72)		(3,756.92)
Net cash flow from / (used in) investing activities (B)		(246.72)		(3,756.92)



C. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from Shares issued [Net of Conversion of Warrants]	6.75		6.04
Borrowings	276.57		219.46
Interest Expenses	(25.06)		(75.44)
Proceeds from Minorities	-	258.26	9.55
Dividends paid[Inclusive of tax on Dividend]	-		1.81
			161.42
Net cash flow from / (used in) financing activities (C)		258.26	
Net increase / (decrease) in Cash and cash equivalents (A+B+C)		(634.11)	970.39
Cash and cash equivalents at the beginning of the year		1,250.05	279.66
Cash and cash equivalents at the end of the year		615.94	1,250.05
Cash and cash equivalents at the end of the year *			
* Comprises:			
(a) Cash on hand	1.26		0.85
(b) Balances with banks	610.80		1,245.32
(i) In current accounts	3.88		3.88
(ii) In earmarked accounts	615.94		1,250.05



For and on behalf of the Board of Directors
 Mukund P. Mehta
 Managing Director

Place : Mumbai
 Dated : 12th November, 2021